Literature DB >> 28096247

Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.

David G Kent1,2, Anthony R Green1,2,3.   

Abstract

Cancers evolve as a consequence of multiple somatic lesions, with competition between subclones and sequential subclonal evolution. Some driver mutations arise either early or late in the evolution of different individual tumors, suggesting that the final malignant properties of a subclone reflect the sum of mutations acquired rather than the order in which they arose. However, very little is known about the cellular consequences of altering the order in which mutations are acquired. Recent studies of human myeloproliferative neoplasms show that the order in which individual mutations are acquired has a dramatic impact on the cell biological and molecular properties of tumor-initiating cells. Differences in clinical presentation, complications, and response to targeted therapy were all observed and implicate mutation order as an important player in cancer biology. These observations represent the first demonstration that the order of mutation acquisition influences stem and progenitor cell behavior and clonal evolution in any cancer. Thus far, the impact of different mutation orders has only been studied in hematological malignancies, and analogous studies of solid cancers are now required.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28096247      PMCID: PMC5378012          DOI: 10.1101/cshperspect.a027060

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  63 in total

Review 1.  The myeloproliferative disorders.

Authors:  Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

Review 2.  From microscopes to microarrays: dissecting recurrent chromosomal rearrangements.

Authors:  Beverly S Emanuel; Sulagna C Saitta
Journal:  Nat Rev Genet       Date:  2007-11       Impact factor: 53.242

Review 3.  Two genetic hits (more or less) to cancer.

Authors:  A G Knudson
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

Review 4.  Cancer genetics: from Boveri and Mendel to microarrays.

Authors:  A Balmain
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 5.  JAK-2 mutations and their relevance to myeloproliferative disease.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Curr Opin Hematol       Date:  2007-01       Impact factor: 3.284

Review 6.  Modelling the molecular circuitry of cancer.

Authors:  William C Hahn; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 7.  A census of human cancer genes.

Authors:  P Andrew Futreal; Lachlan Coin; Mhairi Marshall; Thomas Down; Timothy Hubbard; Richard Wooster; Nazneen Rahman; Michael R Stratton
Journal:  Nat Rev Cancer       Date:  2004-03       Impact factor: 60.716

8.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

Review 9.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

10.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962

View more
  15 in total

Review 1.  Big Bang Tumor Growth and Clonal Evolution.

Authors:  Ruping Sun; Zheng Hu; Christina Curtis
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Modeling Leukemia with Human Induced Pluripotent Stem Cells.

Authors:  Eirini P Papapetrou
Journal:  Cold Spring Harb Perspect Med       Date:  2019-12-02       Impact factor: 6.915

3.  HOXA9 has the hallmarks of a biological switch with implications in blood cancers.

Authors:  Laure Talarmain; Matthew A Clarke; David Shorthouse; Lilia Cabrera-Cosme; David G Kent; Jasmin Fisher; Benjamin A Hall
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

Review 4.  The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters.

Authors:  Arnold J Levine; Nancy A Jenkins; Neal G Copeland
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

Review 5.  Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma.

Authors:  Weibin Hou; Zhigang Ji
Journal:  Exp Mol Med       Date:  2018-04-13       Impact factor: 8.718

6.  Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient.

Authors:  Lidia Franco-Luzón; Sandra García-Mulero; Rebeca Sanz-Pamplona; Gustavo Melen; David Ruano; Álvaro Lassaletta; Luís Madero; África González-Murillo; Manuel Ramírez
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

7.  Estimating the predictability of cancer evolution.

Authors:  Sayed-Rzgar Hosseini; Ramon Diaz-Uriarte; Florian Markowetz; Niko Beerenwinkel
Journal:  Bioinformatics       Date:  2019-07-15       Impact factor: 6.937

8.  Relating evolutionary selection and mutant clonal dynamics in normal epithelia.

Authors:  Michael W J Hall; Philip H Jones; Benjamin A Hall
Journal:  J R Soc Interface       Date:  2019-07-31       Impact factor: 4.118

9.  Molecular Biology and Evolution of Cancer: From Discovery to Action.

Authors:  Jason A Somarelli; Heather Gardner; Vincent L Cannataro; Ella F Gunady; Amy M Boddy; Norman A Johnson; Jeffrey Nicholas Fisk; Stephen G Gaffney; Jeffrey H Chuang; Sheng Li; Francesca D Ciccarelli; Anna R Panchenko; Kate Megquier; Sudhir Kumar; Alex Dornburg; James DeGregori; Jeffrey P Townsend
Journal:  Mol Biol Evol       Date:  2020-02-01       Impact factor: 16.240

10.  Functional characterization of phospholipase C-γ2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder.

Authors:  Claudia Walliser; Martin Wist; Elisabeth Hermkes; Yuan Zhou; Anja Schade; Jennifer Haas; Julia Deinzer; Laurent Désiré; Shawn S C Li; Stephan Stilgenbauer; Joshua D Milner; Peter Gierschik
Journal:  Oncotarget       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.